文献速递生殖医学

替西罗莫司与抗苗勒管激素在小鼠模型中保护生育力和卵巢储备免受化疗损伤

Temsirolimus and antimüllerian hormone protect fertility and the ovarian reserve against chemotherapy-induced damage in a murine model.
PubMed 文献 · Fertil Steril · 2025-07-23

37只雌性小鼠分为对照组、化疗组和性腺保护组,化疗采用环磷酰胺120 mg/kg联合白消安12 mg/kg。性腺保护组在化疗前一周接受5 mg/kg替西罗莫司五次注射,化疗后24小时内接受5 μg重组抗苗勒管激素五次注射。结果显示替西罗莫司联合抗苗勒管激素可保护卵巢储备和生育力。

要点

  • 性腺保护组获卵数36.27±17.22,与对照组41.40±14.74相近,化疗组显著降低至20.63±12.12。
  • 性腺保护组总卵泡数714.4±283.9,与对照组897.4±392.8无差异,化疗组显著降至320.7±145.5。
  • 卵泡凋亡和激活在各组间无显著差异,化疗组卵泡增殖率59.38%±14.67%高于对照组20.72%±10.52%。

核心结论

  • 替西罗莫司与抗苗勒管激素在小鼠模型中显示出作为性腺保护剂的潜力,可能保护卵巢储备免受化疗损伤从而保存生育力,或为无法受益于现有技术的患者提供全新的生育力保存选择。

研究设计与样本

  • 37只Naval Medical Research Institute雌性小鼠随机分入对照组(n=10)、化疗组(n=13)和性腺保护组(n=14)。
  • 化疗组接受单次100 μL注射,含环磷酰胺120 mg/kg和白消安12 mg/kg。
  • 性腺保护组在化疗前一周内接受五次5 mg/kg替西罗莫司注射,化疗后24小时内接受五次5 μg重组抗苗勒管激素注射。
  • 治疗五周后行卵巢刺激并与雄性交配评估残余生育力,交配两天后处死收集胚胎并取卵巢评估卵巢储备和卵泡损伤。

主要发现

  • 对照组获卵数最高(41.40±14.74),性腺保护组紧随其后(36.27±17.22),化疗组(20.63±12.12)较两组均显著降低。
  • 对照组总卵泡数最高(897.4±392.8),与性腺保护组(714.4±283.9)无差异,化疗组(320.7±145.5)较两组均显著下降。
  • 卵泡凋亡和激活在各组间无显著差异。
  • 化疗组卵泡增殖率(59.38%±14.67%)显著高于对照组(20.72%±10.52%),性腺保护治疗(42.23%±18.37%)较化疗组降低卵泡增殖。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the effects of temsirolimus (Tem) and recombinant antimüllerian hormone (AMH) on fertility and the ovarian reserve when associated with chemotherapy. DESIGN: Thirty-seven female mice were assigned to one of three treatment groups: control group; chemotherapy group; and gonadoprotection group. Five weeks after treatment, the mice underwent ovarian stimulation and were mated with males to evaluate residual fertility. Two days after mating, the animals were euthanized for embryo collection, and the ovaries were retrieved to assess the ovarian reserve and follicle damage. SUBJECTS: Thirty-seven Naval Medical Research Institute mice. EXPOSURE: The control group (n = 10) was given a 100-μL injection of phosphate-buffered saline. The chemotherapy group (n = 13) received a single 100-μL injection of chemotherapy (120-mg/kg cyclophosphamide and 12-mg/kg busulfan). The gonadoprotection group (n = 14) was administered five injections of 5-mg/kg Tem over 1 week prior to chemotherapy, followed by a chemotherapy injection and then five injections of 5-μg recombinant AMH over the next 24 hours. MAIN OUTCOME MEASURES: Embryo count, follicle count and morphology, and immunostaining for apoptosis (cleaved caspase-3), follicle activation (phospho-Akt), and proliferation (Ki67). RESULTS: The control group showed the highest mean number of retrieved embryos (41.40 ± 14.74), closely followed by the gonadoprotection group (36.27 ± 17.22), whereas the chemotherapy group exhibited a significant reduction (20.63 ± 12.12) compared to both groups. Regarding the ovarian reserve, the control group showed the highest total follicle count (897.4 ± 392.8), with no difference compared to the gonadoprotection group (714.4 ± 283.9); however, there was a significant decline in the chemotherapy group (320.7 ± 145.5) compared with those in both groups. In terms of follicle apoptosis and activation, no significant difference was observed between groups. Follicle proliferation rates were significantly higher in the chemotherapy group (59.38% ± 14.67%) than in the control group (20.72% ± 10.52%); but gonadoprotective treatment did curtail follicle proliferation (42.23% ± 18.37%) compared with the chemotherapy group. CONCLUSION: Our findings suggest that Tem and AMH show promise as gonadoprotective agents, potentially protecting the ovarian reserve against chemotherapy and thereby preserving fertility. This could offer patients who cannot benefit from currently available techniques brand new fertility preservation options.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Houeis L, van der Plancke G, Cacciottola L, et al. Temsirolimus and antimüllerian hormone protect fertility and the ovarian reserve against chemotherapy-induced damage in a murine model. Fertil Steril. 2025. PMID: 40712967. doi:10.1016/j.fertnstert.2025.07.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。